GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bafna Pharmaceuticals Ltd (BOM:532989) » Definitions » Quick Ratio

Bafna Pharmaceuticals (BOM:532989) Quick Ratio : 0.00 (As of Dec. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Bafna Pharmaceuticals Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Bafna Pharmaceuticals's quick ratio for the quarter that ended in Dec. 2024 was 0.00.

Bafna Pharmaceuticals has a quick ratio of 0.00. It indicates that the company cannot currently fully pay back its current liabilities.

The historical rank and industry rank for Bafna Pharmaceuticals's Quick Ratio or its related term are showing as below:

BOM:532989' s Quick Ratio Range Over the Past 10 Years
Min: 0.53   Med: 1.24   Max: 1.69
Current: 1.24

During the past 13 years, Bafna Pharmaceuticals's highest Quick Ratio was 1.69. The lowest was 0.53. And the median was 1.24.

BOM:532989's Quick Ratio is ranked worse than
54.43% of 1027 companies
in the Drug Manufacturers industry
Industry Median: 1.37 vs BOM:532989: 1.24

Bafna Pharmaceuticals Quick Ratio Historical Data

The historical data trend for Bafna Pharmaceuticals's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bafna Pharmaceuticals Quick Ratio Chart

Bafna Pharmaceuticals Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.43 1.41 1.39 1.40 1.20

Bafna Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 1.20 - 1.24 -

Competitive Comparison of Bafna Pharmaceuticals's Quick Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Bafna Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bafna Pharmaceuticals's Quick Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bafna Pharmaceuticals's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Bafna Pharmaceuticals's Quick Ratio falls into.


;
;

Bafna Pharmaceuticals Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Bafna Pharmaceuticals's Quick Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Quick Ratio (A: Mar. 2024 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(944.699-296.418)/540.83
=1.20

Bafna Pharmaceuticals's Quick Ratio for the quarter that ended in Dec. 2024 is calculated as

Quick Ratio (Q: Dec. 2024 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(0-0)/0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bafna Pharmaceuticals  (BOM:532989) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Bafna Pharmaceuticals Quick Ratio Related Terms

Thank you for viewing the detailed overview of Bafna Pharmaceuticals's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Bafna Pharmaceuticals Business Description

Traded in Other Exchanges
Address
Thambu Chetty Street, New No. 68, Old No.299, Bafna Towers, Chennai, TN, IND, 600001
Bafna Pharmaceuticals Ltd is an India-based pharmaceutical company. It is principally engaged in the manufacturing and marketing of drugs and medicines. The company sells its products in India and international regions. The company has only one Segment of Business namely Pharmaceuticals.

Bafna Pharmaceuticals Headlines

No Headlines